Annie Guérin

6.3k total citations · 2 hit papers
220 papers, 4.5k citations indexed

About

Annie Guérin is a scholar working on Hematology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Annie Guérin has authored 220 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Hematology, 50 papers in Genetics and 41 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Annie Guérin's work include Chronic Myeloid Leukemia Treatments (43 papers), Chronic Lymphocytic Leukemia Research (42 papers) and Acute Lymphoblastic Leukemia research (18 papers). Annie Guérin is often cited by papers focused on Chronic Myeloid Leukemia Treatments (43 papers), Chronic Lymphocytic Leukemia Research (42 papers) and Acute Lymphoblastic Leukemia research (18 papers). Annie Guérin collaborates with scholars based in United States, Canada and Switzerland. Annie Guérin's co-authors include Eric Q. Wu, Martin Cloutier, Andrew P. Yu, Parvez Mulani, Patrick Gagnon‐Sanschagrin, Dominick Latrémouille-Viau, Irina Pivneva, Marjolaine Gauthier‐Loiselle, Roy Nitulescu and Mei Sheng Duh and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Annie Guérin

208 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Economic Burden of Schizophrenia in the United States in 2013

2016 358 citations Martin Cloutier, Myrlene Sanon Aigbogun et al. profile →
The Economic Burden of Posttraumatic Stress Disorder in the United States From a Societal Perspective

2022 108 citations Lori L. Davis, Jeff Schein et al. profile →

Peers

Countries citing papers authored by Annie Guérin

Since Specialization

Citations

This map shows the geographic impact of Annie Guérin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annie Guérin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annie Guérin more than expected).

Fields of papers citing papers by Annie Guérin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annie Guérin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annie Guérin. The network helps show where Annie Guérin may publish in the future.

Co-authorship network of co-authors of Annie Guérin

This figure shows the co-authorship network connecting the top 25 collaborators of Annie Guérin. A scholar is included among the top collaborators of Annie Guérin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annie Guérin. Annie Guérin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Assessment of Access Barriers to Rifaximin Among Patients with Hepatic Encephalopathy Using Adjudicated Claims Data 2025 ·Advances in Therapy ·Arun Jesudian, Patrick Gagnon‐Sanschagrin, Jessica Maitland, (unknown), Annie Guérin, (unknown), (unknown), (unknown), (unknown)	0
2	Agitation in individuals with Alzheimer’s disease: An assessment of behaviors using the cohen-mansfield agitation inventory in community-dwellers and impact on caregiver experience 2025 ·Dementia ·George T. Grossberg, Cynthia Willey, Christy R. Houle, Jeff Schein, (unknown), Martin Cloutier, Marjolaine Gauthier‐Loiselle, Deborah Chan, Annie Guérin, Zahinoor Ismail, Jyoti Aggarwal	1
3	Real-World Trends and Future Projections of the Prevalence of Cirrhosis and Hepatic Encephalopathy Among Commercially and Medicare-Insured Adults in the United States 2025 ·Clinical and Translational Gastroenterology ·Robert J. Wong, Patrick Gagnon‐Sanschagrin, (unknown), Jessica Maitland, (unknown), Annie Guérin, (unknown), (unknown), (unknown)	0
4	Treatment with asciminib after a prior tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia 2025 ·Leukemia Research ·Ehab Atallah, (unknown), David Wei, Dominick Latrémouille-Viau, Carmine Rossi, (unknown), (unknown), (unknown), Annie Guérin, Kejal Parikh	1
5	The economic impact of suboptimal treatment and treatment switch among patients with Crohn’s disease treated with a first-line biologic – A US retrospective claims database study 2024 ·Journal of Medical Economics ·Patrick Gagnon‐Sanschagrin, (unknown), M. Davidson, Cynthia Willey, Sumesh Kachroo, Timothy Hoops, (unknown), Annie Guérin, Martin Cloutier	1
6	Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States 2023 ·Journal of health economics and outcomes research ·Prateek Sharma, Gary W. Falk, Menaka Bhor, A. Burak Ozbay, Dominick Latrémouille-Viau, Annie Guérin, Sherry Shi, Margaret Elvekrog, Paul J. Limburg	2
7	Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States 2023 ·Journal of health economics and outcomes research ·Prateek Sharma, Gary W. Falk, Menaka Bhor, A. Burak Ozbay, Dominick Latrémouille-Viau, Annie Guérin, Sherry Shi, Margaret Elvekrog, Paul J. Limburg	6
8	Su1137 SUBOPTIMAL TREATMENT IN PATIENTS WITH CROHN'S DISEASE USING BIOLOGICS 2023 ·Gastroenterology ·Patrick Gagnon‐Sanschagrin, (unknown), M. Davidson, Cynthia Willey, Sumesh Kachroo, Timothy Hoops, (unknown), Annie Guérin, Martin Cloutier	1
9	A real-world assessment of healthcare costs associated with agitation in Alzheimer’s dementia 2023 ·Journal of Medical Economics ·George T. Grossberg, Annette Urganus, Jeff Schein, (unknown), Martin Cloutier, Marjolaine Gauthier‐Loiselle, Deborah Chan, Annie Guérin, Jyoti Aggarwal	5
10	Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costs 2023 ·Journal of Medical Economics ·Arun Jesudian, Patrick Gagnon‐Sanschagrin, (unknown), (unknown), Jingyi Chen, Annie Guérin, (unknown), (unknown), George Joseph, (unknown)	2
11	Reasons for Treatment Changes in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Chart Review Study 2022 ·Advances in Therapy ·Jeff Schein, Martin Cloutier, Marjolaine Gauthier‐Loiselle, (unknown), Annie Guérin, Ann Childress	9
12	Prevalence of post-traumatic stress disorder in the United States: a systematic literature review 2021 ·Current Medical Research and Opinion ·Jeffrey Schein, Christy R. Houle, Annette Urganus, Martin Cloutier, Oscar Patterson‐Lomba, Yao Wang, Sarah King, (unknown), Annie Guérin, Patrick Lefèbvre, Lori L. Davis	132
13	The societal economic burden of autosomal dominant polycystic kidney disease in the United States 2020 ·BMC Health Services Research ·Martin Cloutier, Ameur M. Manceur, Annie Guérin, Myrlene Sanon Aigbogun, Dorothee Oberdhan, Marjolaine Gauthier‐Loiselle	26
14	Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) 2020 ·Blood ·Sudipto Mukherjee, Xiting Cao, (unknown), Rodrigo Maegawa, Dominick Latrémouille-Viau, Irina Pivneva, Annie Guérin, Benjamin D. Smith	0
15	Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis 2019 ·Blood ·Eytan M. Stein, Dominick Latrémouille-Viau, George J Joseph, Sherry Shi, Annie Guérin, Eric Q. Wu, Gaetano Bonifacio, Xiting Cao	7
16	Increased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based Analysis. 2018 ·PubMed ·Alexa B. Kimball, Murali Sundaram, Martin Cloutier, Marjolaine Gauthier‐Loiselle, Patrick Gagnon‐Sanschagrin, Annie Guérin, Arijit Ganguli	4
17	Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis. 2018 ·PubMed ·Amy S. Paller, Rakesh Singh, Martin Cloutier, Marjolaine Gauthier‐Loiselle, Bruno Émond, Annie Guérin, Arijit Ganguli	41
18	Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in US Clinical Practice, with a Focus on Tyrosine Kinase Inhibitor Therapy Discontinuation 2017 ·Blood ·Ellen K. Ritchie, Dominick Latrémouille-Viau, Annie Guérin, Irina Pivneva, (unknown), (unknown), George J Joseph, Ehab Atallah	1
19	Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2− metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis 2016 ·Journal of Medical Economics ·Nanxin Li, Yanni Hao, (unknown), (unknown), (unknown), Andrew Kageleiry, Eric Q. Wu, Annie Guérin	4
20	Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers 2011 ·Journal of Medical Economics ·Andrew P. Yu, Annie Guérin, (unknown), Karthik Ramakrishnan, Eric Q. Wu, Michelle Mocarski, (unknown), Juliana Setyawan	128

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact